The Exaggerated Glucagon-like Peptide-1 Response is Important for the Improved β-cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hvidovre University Hospital
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Beta cell glucose sensitivity
Study Overview
Brief Summary
After Roux-en-Y gastric bypass (RYGB) meal induced GLP-1 secretion is dramatically increased, while beta-cell function is increased in type 2 diabetic (T2D) subjects. The aim of this study is to establish causality between the two observations. By meal testing 10 T2D subjects with infusion of saline or exendin (9-39), a GLP-1R specific blocker, before and 1 week and 3 months after RYGB we hope to demonstrate the role of GLP-1 in improveing beta-cell function and maintaing glucose tolerance after RYGB in T2D subjects. Furthermore, effects of GLP-1 rec blockade before and after RYGB on ad libitum energy intake is examined
Detailed Description
After Roux-en-Y gastric bypass (RYGB) meal induced GLP-1 secretion is dramatically increased, while beta-cell function is increased in type 2 diabetic (T2D) subjects. The aim of this study is to establish causality between the two observations. By meal testing 10 T2D subjects with infusion of saline or exendin (9-39), a GLP-1R specific blocker, before and 1 week and 3 months after RYGB we hope to demonstrate the role of GLP-1 in improveing beta-cell function and maintaing glucose tolerance after RYGB in T2D subjects. Furthermore, effects of GLP-1 rec blockade before and after RYGB on ad libitum energy intake is examined
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 25 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Fasting glucose > 7.0 mM, 2h glucose after OGTT > 11.0 mM. BMI >
- •HbA1c < 8.5%. Fasting C-peptide > 700 pM. Elegible for RYGB.
Exclusion Criteria
- •Dysregulated hypothyroidism, hyperthyroidism, anaemia.
Outcomes
Primary Outcomes
Beta cell glucose sensitivity
Time Frame: 1 week and 3 months after RYGB
change in prehepatic insulin secretionrate relative to glucose increments
Secondary Outcomes
- Glucose tolerance(1 week and 3 months after RYGB)
- Ad libitum food intake(3 months after surgery)
Investigators
Nils Bruun Jørgensen
Klinisk Assistent
Hvidovre University Hospital